Patient-Derived Cells: The Essential Foundation for Personalized Drug Development in Rare Disease

If your child has been diagnosed with a rare genetic disease and you want to take advantage of the new generation of genetic medicines, from ASOs to gene editing to gene therapy, the path to a personalized treatment almost always starts in the same place: a patient-derived cell line.

These are living cells grown from your child's own tissue that carry their exact genetic mutation. They are the platform on which every candidate therapy is designed, screened, and validated before it ever reaches your child. Without them, there is no way to test whether a treatment works. Without them, there is no FDA filing. They are not a nice-to-have. They are the foundation.

In this article, we break down what patient-derived cells are, how they are made, what they cost at each stage, and which disease models are actually possible today.

What Are Patient-Derived Cells?

Patient-derived cells are living cells grown from a sample of your child's tissue, usually from a small skin biopsy or a blood draw. These cells carry your child's complete genome, including the specific mutation that causes their disease. That is what makes them valuable: they are not generic lab cells. They are your child's cells, with your child's mutation, behaving the way your child's cells behave.

Researchers use these cells for several things: to understand what the mutation actually does at the cellular level, to test whether a potential therapy fixes the problem, to measure safety before the therapy is given to your child, and to generate the evidence the FDA requires for regulatory approval.

There are several types of patient-derived cells, ranging from simple (skin fibroblasts you can grow in a few weeks) to complex (brain organoids that take months to develop). Which type your child's program needs depends on what disease they have and which organ is affected.

The Cell Pipeline: From Skin Biopsy to Disease Model

Everything starts with a small tissue sample from your child. The most common approach is a skin punch biopsy, a 2 to 4 millimeter circle of skin taken under local anesthetic in an outpatient visit. It takes about 10 minutes and heals in about a week. Alternatively, researchers can work from a standard blood draw. Both approaches provide cells that carry your child's complete genetic information.

From that starting sample, the pipeline works in stages. Each stage builds on the last and produces a more sophisticated disease model. The total elapsed time from skin biopsy to research-ready disease model cells is typically 3 to 6 months, depending on which cell type is needed. Here is what each step costs and how long it takes:

Stage 1: Fibroblasts (Weeks 1-3, $1,000-$3,000). The skin cells from the biopsy are placed in a dish with growth medium. Over 2 to 3 weeks, cells called fibroblasts grow out from the tissue and multiply. These are your child's skin cells. They carry the mutation. They can be frozen and banked for years. Fibroblasts are the cheapest and fastest patient cells to obtain, and they are useful for initial gene expression testing, some drug screening, and as the starting material for the next step.

Stage 2: iPSCs (Weeks 4-14, $5,000-$20,000). This is the transformative step. Fibroblasts are "reprogrammed" into stem cells using a set of proteins (originally discovered by Shinya Yamanaka, who won the Nobel Prize for this work in 2012). The resulting cells, called iPSCs, are essentially returned to an embryonic-like state. They can become almost any cell type in the human body. This step alone takes 8 to 12 weeks and the cost depends on the lab, the number of clones generated, and the quality control performed. Cumulative elapsed time at this point: roughly 3 months.

Stage 3: Differentiated cells (Weeks 15-26+, $10,000-$30,000). iPSCs are then guided, using specific growth factors and culture conditions, into the cell type affected by your child's disease. If the disease affects the brain, researchers differentiate iPSCs into neurons. If it affects the liver, into hepatocytes. If it affects the eyes, into retinal pigment epithelium (RPE) or photoreceptor cells. These differentiated cells now carry your child's mutation in the right tissue context. This is the disease model. Additional time ranges from 2 weeks (for cardiomyocytes) to 20+ weeks (for photoreceptors). Cumulative elapsed time: 4 to 6+ months depending on cell type.

Stage 4: Organoids (add 4-24 weeks, $15,000-$50,000+). The most advanced step, and not available for every tissue type. Organoids are three-dimensional, miniature organ-like structures grown from iPSCs. They are the closest thing to a real organ you can grow in a dish. They take months and cost $15,000 to $50,000 or more. But crucially, not all organoids are equally mature or available. See the section below on which are actually feasible today.

Cell Types Explained: From Easiest to Most Complex

Not every program needs every cell type. For many ASO programs, fibroblasts or basic iPSC-derived cells are sufficient to screen candidates and measure efficacy. For gene editing programs, iPSC-derived cells in the target tissue are typically needed. The key question to ask your research team early: do we need a 3D organoid, or will a 2D differentiated culture give us the data we need to move forward? The answer depends on the disease, the tissue, and what is actually possible today.

Beyond iPSCs: Differentiating Cells into 2D and 3D Disease Models

Once you have iPSCs, the next question is: what do you turn them into? The answer depends on your child's disease and which tissue is affected. Researchers "differentiate" iPSCs into specific cell types using growth factors and culture conditions that mimic how those cells develop in the body. The result is a 2D culture of the disease-relevant cell type (a flat layer of neurons, liver cells, or heart cells in a dish) or, for some tissues, a 3D organoid (a miniature organ-like structure with multiple cell types organized in layers).

Not all cell types are equally easy to make, and not all tissues can be grown as 3D organoids. This matters for your child's program because it directly affects the timeline, cost, and which labs can do the work.

Liver cells and heart cells are among the easiest and fastest: 2 to 4 weeks after iPSCs are ready, with well-established protocols at most stem cell labs. Neurons are more complex, ranging from 4 weeks for motor neurons to 12+ weeks for mature cortical neurons. Photoreceptors (for retinal diseases like retinitis pigmentosa) are among the hardest 2D differentiations, requiring 16 to 20 weeks. Skeletal muscle can be differentiated into myotubes in 2D but the cells are less mature than native muscle fibers.

For many ASO and gene editing programs, these 2D cultures are sufficient. They carry the patient's mutation, they produce the disease phenotype, and they can be used to screen candidates and generate the efficacy data needed for an FDA filing. The question of whether you need to go further, into 3D organoids, depends on the disease.

3D Organoids: Which Can Actually Be Made Today?

Organoids are three-dimensional structures grown from iPSCs that self-organize into miniature organ-like architectures. They are more physiologically relevant than 2D cultures because they contain multiple cell types interacting in spatial arrangements that mimic real tissue. But not all organ types can be grown as organoids. Here is the definitive breakdown.

For most ASO programs, 2D cultures are sufficient. For gene therapy and gene editing programs targeting complex tissues, organoids may add significant value. Starting with the simplest sufficient model saves months and tens of thousands of dollars.

Why Patient Cells Are Not Optional

Patient-derived cells are required infrastructure for developing any individualized therapy. Without them, researchers cannot confirm that the mutation causes the expected cellular dysfunction, screen ASO candidates or gene editing guides, measure whether a therapy restores function, perform the safety testing (off-target analysis) required for gene editing, or generate the evidence the FDA requires for an IND filing.

In the Baby KJ case, patient-derived cells were central to every stage: the base editor was tested on cells carrying KJ's mutation, the off-target analysis was performed on KJ's genome, and the preclinical evidence package submitted to the FDA was built on patient cell data.

Skin Biopsy vs. Blood Draw: Which Starting Material Is Better?

Both work. A skin punch biopsy is the most common starting point because fibroblasts grow out of the tissue quickly and reliably, and the reprogramming efficiency from fibroblasts to iPSCs is high. The biopsy itself is small (2-4mm), uses local anesthetic, and heals within a week.

A standard blood draw is the alternative. Peripheral blood mononuclear cells (PBMCs) can be reprogrammed into iPSCs using the same technology. The success rate is slightly lower and the process can be less efficient, but it avoids a biopsy entirely. This is particularly useful for infants or children where a skin biopsy is difficult or for families who prefer to avoid any minor procedure.

For ASO programs specifically, fibroblasts from a skin biopsy are usually the first choice because they are the most reliable and efficient starting material. But for families where a biopsy is not practical, blood-derived iPSCs are a well-validated alternative. Either way, the resulting iPSCs are functionally equivalent.

COMBINEDBrain: How Disease Communities Are Pooling Cell Banking Resources

One of the most important developments in patient cell infrastructure is COMBINEDBrain, a nonprofit consortium founded by Dr. Terry Jo Bichell, a neuroscientist and the mother of a son with Angelman syndrome. COMBINEDBrain represents more than 65 rare genetic neurodevelopmental disorder advocacy groups and operates a centralized biorepository in partnership with IBX.

The model is straightforward: families donate blood samples or skin biopsies at coordinated collection events. COMBINEDBrain's lab partner isolates fibroblasts and PBMCs, generates iPSC lines, and banks everything in a centralized, HIPAA-compliant repository. Those samples are then made available to researchers and industry at the lowest possible cost, with de-identified health histories attached so that biological data can be properly interpreted.

Foundations like the CACNA1A Foundation have invested over $50,000 in iPSC lines through COMBINEDBrain and now have 8 completed patient-derived iPSC lines available for researchers (CACNA1A Foundation, cacna1a.org, August 2024). The Hereditary Neuropathy Foundation (HNF) launched the first-ever CMT Biobank through the same partnership (HNF press release, August 2023). The Foundation for Prader-Willi Research has built a dedicated Schaaf-Yang syndrome biorepository through COMBINEDBrain as well (FPWR, fpwr.org, November 2025).

This model is replicable for any rare disease community. If your foundation or patient group does not yet have banked cell lines, COMBINEDBrain offers the infrastructure to start. Nome works with COMBINEDBrain and similar biorepositories to ensure our patients' cell lines are banked, tracked, and available for downstream therapeutic development.

What Should You Do Right Now?

If your child has a confirmed genetic diagnosis and you are exploring treatment options, the single most valuable thing you can do immediately is establish a banked fibroblast line from a skin biopsy. This is fast (2 to 3 weeks), relatively inexpensive ($1,000 to $3,000), and gives your child's future research team the starting material they need for any downstream work.

You do not need to wait until a therapy approach has been selected. You do not need to wait until a research team has been identified. A banked fibroblast line is useful regardless of whether the eventual therapy is an ASO, gene therapy, gene editing, or drug repurposing. It is the raw material that makes everything else possible.

Ask your child's geneticist or neurologist about arranging a skin biopsy. Many academic medical centers can process and bank the sample. If your disease community has a relationship with COMBINEDBrain, their next collection event may be the easiest path. If none of those options are available, Nome can connect you with a qualified lab.

What Nome Does

Nome includes cell line strategy as part of every patient evaluation. When we assess your child's mutation, we determine which cell types the program will need, identify the right labs to generate them, estimate the cost and timeline, and coordinate the biopsy and banking process if it has not already been done. We work with partners including COMBINEDBrain's biorepository network to ensure samples are banked, tracked, and available for downstream therapeutic development.

For active programs, we manage the full cell line pipeline: from biopsy logistics to iPSC reprogramming to differentiation into the target tissue. We know which CROs deliver on time, which labs have the right expertise for each tissue type, and how to sequence the work so it does not become a bottleneck.

The first step is always the same: get a genetic diagnosis, then find out what is possible.

Submit your child's genetic diagnosis for a free evaluation at nome.bio.

REFERENCES

1. Takahashi K, Yamanaka S. Cell. 2006;126(4):663-676. (Discovery of iPSC reprogramming)

2. Francis KR, Chen G, Kiris E. Front Cell Dev Biol. 2025. (iPSC-based model systems for rare diseases)

3. Wiley LA, et al. Curr Protoc Hum Genet. 2016. (cGMP-compliant iPSC from skin biopsy)

4. Ahrens-Nicklas R, Musunuru K, et al. NEJM. 2025. (Baby KJ, patient cell use in gene editing)

5. Evotec. "iPSC Drug Discovery Platform." evotec.com. (20+ differentiated cell types)

6. Lancaster MA, Knoblich JA. Science. 2014;345(6194):1247125. (Cerebral organoids)

7. Bichell TJ. Once Upon A Gene podcast, Episode 217. February 2024. (COMBINEDBrain, 900+ individuals)

8. CACNA1A Foundation. "Biobanking." cacna1a.org. August 2024. (8 iPSC lines, $50K+ invested)

9. Hereditary Neuropathy Foundation. "First Ever Biorepository for CMT." HNF press release, August 2023.

10. Foundation for Prader-Willi Research. "Building the SYS Biorepository." fpwr.org, November 2025.

This article is for informational purposes only and does not constitute medical advice.